News

29

Jun, 2018

ODYSSEY: recruitment has completed!

 

We are pleased to announce that recruitment to the main trial has now completed. We have recruited slightly more than the total target of 700 participants: 312 recruited into ODYSSEY A (naïve to HIV treatment) and 396 into ODYSSEY B (starting second line HIV treatment).

READ MORE

26

Jun, 2018

Early and highly suppressive ART are main factors associated with low viral reservoir in European perinatally HIV infected children

 

Authors: Tagarro A, Chan M, Zangari P, et al; on behalf of the EPIICAL Consortium Published in: J Acquir Immune Defic Syndr. 2018;79(2):269-276 Background Future strategies aiming to achieve HIV-1 remission are likely to target individuals with small reservoir size. Setting We retrospectively investigated factors associated with HIV-1 DNA levels in European, perinatally HIV-infected children starting ART <6 months of age. Methods Total HIV-1 DNA was measured from 51 long-term suppressed children 6.3 years (median) after initial viral suppression. Factors associated with log10 total HIV-1 DNA were analyzed using linear regression. Results At ART initiation, children were aged median [IQR] 2.3 [1.2,4.1] months, CD4% 37 [24,45] %, CD8% 28 [18,36] %, log10 plasma viral load (VL) […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities